0000950170-24-024298.txt : 20240301 0000950170-24-024298.hdr.sgml : 20240301 20240301213715 ACCESSION NUMBER: 0000950170-24-024298 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240229 FILED AS OF DATE: 20240301 DATE AS OF CHANGE: 20240301 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Scalzo Richard William CENTRAL INDEX KEY: 0001789545 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39509 FILM NUMBER: 24712682 MAIL ADDRESS: STREET 1: 25 ALBERTA LANE CITY: HOLLISTON STATE: MA ZIP: 01746 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Dyne Therapeutics, Inc. CENTRAL INDEX KEY: 0001818794 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 364883909 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1560 TRAPELO ROAD CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: (781) 786-8230 MAIL ADDRESS: STREET 1: 1560 TRAPELO ROAD CITY: WALTHAM STATE: MA ZIP: 02451 4 1 ownership.xml 4 X0508 4 2024-02-29 0001818794 Dyne Therapeutics, Inc. DYN 0001789545 Scalzo Richard William 1560 TRAPELO ROAD WALTHAM MA 02451 false true false false SVP, Head of Finance & Admin. true Common Stock 2024-02-29 4 M false 3429 1.03 A 127657 D Common Stock 2024-02-29 4 S false 3429 27.50 D 124228 D Common Stock 2024-03-01 4 M false 9311 1.03 A 133539 D Common Stock 2024-03-01 4 S false 8747 28.22 D 124792 D Common Stock 2024-03-01 4 S false 564 28.65 D 124228 D Stock option (right to buy) 1.03 2024-02-29 4 M false 3429 0 D 2030-01-05 Common Stock 3429 9311 D Stock option (right to buy) 1.03 2024-03-01 4 M false 9311 0 D 2030-01-05 Common Stock 9311 0 D Includes 118,605 unvested RSUs. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 11, 2023. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $27.50 to $27.58, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $27.50 to $28.48, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $28.55 to $28.83, inclusive. The option was granted on January 6, 2020. The shares underlying the option vest over four years, with 25% of the shares vesting on December 2, 2020 and the remaining shares vesting in equal quarterly installments thereafter. /s/ Richard Scalzo 2024-03-01